Objective: To provide a review on the use, percent positive agreement (PPA), percent negative agreement (PNA), and implementation of using the OraQuick HCV Rapid Antibody Test for hepatitis C virus (HCV) screening in community pharmacies in an effort to increase overall HCV screening in target populations. Data Sources: PubMed and Sagepub were searched for the following keywords: hepatitis C virus, rapid diagnostic tests, rapid assay, and rapid HCV assay. Dates searched were from January 2000 to October 2013. Study Selection: All studies including the use of the OraQuick HCV Rapid Antibody Test were included. Data Synthesis: Sensitivity and specificity of this device are compared with several standard laboratory tests for detecting HCV antibodies. In comparing these values with the clinical “standards,” PPA and PNA are more applicable terms to describe whether the OraQuick device is an effective tool for initial screening by pharmacists. The OraQuick HCV Rapid Antibody Test demonstrates high accuracy in providing accurate HCV infection status. Conclusion: The OraQuick HCV Rapid Antibody Test is a unique tool pharmacists can use in an effort to enhance the screening capabilities for HCV infection. Pharmacists often have the most contact with those patients at high risk for having contracted HCV in the past. With a relatively high PPA and high NPA, a high confidence in the accuracy of the device can be placed on initial test results. Patients should then be triaged to proper follow-up care depending on initial results.
ArmstrongGLWasleyASimardEPMcQuillanGMKuhnertWLAlterMJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705-714.
2.
Centers for Disease Control and Prevention. Recommen-dations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep. 2012;61(RR-4):1-32.
3.
Centers for Disease Control and Prevention. Testing for HCV infection: an update of guidance for clinicians and laboratorians. MMWR Morb Mortal Wkly Rep. 2013;62(18):362-365.
4.
ReinDBWittenbornJSWeingbaumCMSabinMSmithBDLesesnesB. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis. 2011;43:66-72.
5.
LyKNXingJKlevensRMJilesRBWardJWHolmbergSD. The increasing burden of mortality from viral hepatitis in the United States, 1999 through 2002. Ann Intern Med. 2006;156:271-278.
6.
Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep. 1998;47(RR-19):1-39.
7.
KamiliSDrobeniucJAraujoACHaydenTM. Laboratory diagnostics for hepatitis C virus infection. Clin Infect Dis. 2012;55(1):S43-S48.
8.
Centers for Disease Control and Prevention. Guidelines for laboratory testing and result reporting of antibody to hepatitis c virus. MMWR Recomm Rep. 2003;52(RR-3):1-13.
9.
MorettiMPierettiBMasucciASistiDRocchiMDelpreteE. Role of signal-to-cutoff ratios in hepatitis C virus antibody detection. Clin Vaccine Immunol. 2012;19:1329-1331.
10.
SmithBDTeshaleEJewettA. Performance of premarket rapid hepatitis C virus antibody assay in 4 national human immunodeficiency virus behavioral surveillance system sites. Clin Infect Dis. 2011;53:780-786.
11.
SmithBDDrobeniucJJewettA. Evaluation of three rapid screening assays for detection of antibodies to hepatitis C virus. J Infect Dis. 2011;204:825-831.
ChaYJParkQKangE. Performance evaluation of the OraQuick hepatitis c virus rapid antibody test. Ann Lab Med. 2013;33:184-189.
14.
LeeSRKardosKWSchiffE. Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid. J Virol Methods. 2011;172(1-2):27-31.
15.
LeeSRYearwoodGDGuillonGB. Evaluation of a rapid, point-of-care test device for the diagnosis of hepatitis C infection. J Virol Methods. 2010;48(1):15-17.
16.
HeathDKlepserMLoftusS. Screening for human immunodeficiency virus and hepatitis C virus in community pharmacies: an emerging opportunity. Michigan Pharmacists Association. 2012;60(4):40-43.
